X4 Pharmaceuticals, Inc
10-K
March 17, 2026
Key Highlights
- X4 Pharmaceuticals is advancing mavorixafor, a novel oral CXCR4 antagonist, for ...
- Mavorixafor has first-in-class potential for WHIM syndrome, addressing an unmet ...
- Completed enrollment for pivotal Phase 3 WHIM trial, with top-line data anticipa...
Read Analysis
🤖 AI Generated